Todd Garabedian's article, "Determining joint inventorship: antibody paying attention?" was published in The Patent Lawyer Magazine Annual 2021 issue. Their article discusses the tenets of joint inventorship under U.S. law with specific reference to the Dana-Farber decision.

On December 4, 2024, the United States Patent and Trademark Office (“USPTO”) withdrew a proposed rule regarding terminal disclaimer practice to overcome non-statutory double patenting rejections. The proposed rule would have required a patentee to declare that the patent with the terminal disclaimer will be enforceable only if the patent is not tied to and has never been tied to a patent in which any claim has been finally held unpatentable or invalid as anticipated or obvious. Now, the USPTO has withdrawn the proposed rule, citing “resource constraints” as its reason not to move forward. Read more in Cantor Colburn's Client Alert, USPTO Withdraws Proposed Rule Regarding New Terminal Disclaimer Practice.

The USPTO recently announced that its After Final Consideration Pilot Program 2.0 (“AFCP 2.0”) will expire on December 14, 2024.  The AFCP program started in 2013  as part of an effort by the USPTO to reduce the need for Requests For Continued Examination (RCE) by providing an opportunity to obtain consideration of narrowing claim amendments following a “final” Office Action. Because the program could possibly result in allowance and grant of a patent without requiring an additional fee, it has been a popular option for patent applicants.

Cantor Colburn is pleased to announce that Partners Michael Cantor, Nancy Kennedy, Todd Garabedian, and Steve Coyle are 2024 Super Lawyers and Ali Caless is a Super Lawyers Rising Stars. Only 5% of attorneys are selected to be Super Lawyers; only 2.5% of attorneys are selected to be Rising Stars. 

Managing Intellectual Property has recognized seven Cantor Colburn attorneys in its 2024 IP Stars guide, which brings together the world’s foremost law firm and corporate intellectual property experts, allowing the wider community to benefit from their insight, experience and perspectives.

Cantor Colburn LLP, one of the largest full-service intellectual property law firms in the country, is pleased to announce that Partners Michael Cantor and Todd Garabedian are 2023 Super Lawyers and Ali Caless is a Super Lawyers Rising Stars. Only 5% of attorneys are selected to be Super Lawyers; only 2.5% of attorneys are selected to be Rising Stars. 

Cantor Colburn is proud to announce that the following attorneys are recognized as 2024 Best Lawyers: Michael Cantor, Michelle Ciotola, Phil Colburn, Steve Coyle, Todd Garabedian, Ph.D., David Rodrigues, Ph.D., Mike Rye, and Susan Zerull. Ali Caless is Best Lawyers: One to Watch.

Effective April 18, 2023, the U.S. Patent and Trademark Office is transitioning to issuing electronic patent grants - eGrants - to patent recipients rather than paper patents in order to improve the environment and streamline the process of issuing patents.  This change will also increase the speed with which patents are issued, giving applicants reduced timeframes to file continuing applications.  

Cantor Colburn Co-Managing Partners Michael Cantor and Philmore Colburn and Partners Todd Garabedian, Anne Maxwell, David Fox, Leah Reimer, and Karl Vick are 2023 Patent Stars, from Managing Intellectual Property.

On March 16, 2023, the United States Copyright Office (USCO) issued a Statement of Policy titled “Copyright Registration Guidance: Works Containing Material Generated by Artificial Intelligence,” which clarifies the USCO’s practices for examining and registering works that contain material generated using Artificial Intelligence technology. Cantor Colburn offers this Client Alert to examine the issues and what this means for you.

Law360 published the article, "Conn. IP Attys Cite Ethical Unease On Texting, Chinese Filings," written by Sameer Rao on December 7, 2021, which covered the Connecticut Bar Association webinar, "Hot Topics in Ethics for Intellectual Property Attorneys." Todd Garabedian, Partner and Vice Chair of Cantor Colburn's Life Sciences Practice Group, was a panelist.

Cantor Colburn LLP, the #3 firm for patents in the United States, is proud to have been awarded a ten-year, multimillion-dollar contract with the National Institutes of Health (NIH), the largest biomedical research agency in the world, to provide patent legal services in chemistry. 

Todd Garabedian's article, "Determining joint inventorship: antibody paying attention?" for The Patent Lawyer Magazine Annual 2021 issue. Their article discusses the tenets of joint inventorship under U.S. law with specific reference to the Dana-Farber decision.

The USPTO published new examination guidance concerning method-of-treatment claims. Cantor Colburn's Client Alert summarizes the so-called "Vanda memo." In a memorandum dated June 7, 2018, the USPTO set out new examination guidance concerning method-of-treatment claims, which is encouraging news for patent applicants in the personalized medicine space. The memo emphasizes that method of treatment claims can be found to satisfy subject matter eligibility under 35 USC § 101 at the first step of an Alice/Mayo analysis, without requiring a showing of “nonroutine or unconventional steps.” The memo provides helpful guidance to examiners and patent applicants that emphasizes the patent eligibility of personalized method of treatment claims.

Cantor Colburn LLP, one of the country’s leading intellectual property (IP) law firms, announced the hiring of partner Todd E. Garabedian, Ph.D., formerly a partner at Wiggin & Dana LLP. Garabedian, a Ph.D. biochemist, has almost 20 years of extensive experience in patent application preparation, prosecution, counseling, portfolio management, and legal opinions in a wide variety of disciplines related to the biological and chemical sciences. 

BioCT’s Annual Bioscience and Beer Mixer + Special Edition Collaborative CT will be attended by Anne Maxwell, Bryan Zerhusen, Nick Herrel, and Todd Garabedian on September 19, 2024.

The 2023 Northeast Regional Meeting of the American Chemical Society (NERM 2023) will be organized by NESACS and will be hosted at Northeastern University in Boston. An all-star panel from Cantor Colburn LLP will discuss patent protection for innovative products or processes, which excludes others from making and selling the same products or using the same processes, can be critical to the profitability of tech companies. Cantor Colburn is proud to sponsor this meeting. 

The BIO International Convention 2023 is in Boston, June 5-8, 2023. Thousands of biotechnology and pharma leaders will come together for intensive networking to discover new opportunities and partnerships. Cantor Colburn partners Anne Maxwell, Ph.D. and Todd Garabedian, Ph.D. will attend. 

Todd Garabedian, Partner and Vice Chair of the Life Sciences Practice at Cantor Colburn LLP, and other IP lawyers will participate in Diverse Careers in IP, a live panel at Quinnipiac University School of Law presented by the New York Intellectual Property Law Association (NYIPLA) on April 19, 2023. The panel will discuss opportunities for lawyers in today's intellectual property marketplace. 

Todd Garabedian will participate in a panel discussion of Ethics in IP Law on December 7, 2021, presented by the IP section of the Connecticut Bar Association.

Cantor Colburn is proud to sponsor The JAX Healthcare Forum presented by The Jackson Laboratory for Genomic Medicine on October 23-24, 2019, at the Jackson Laboratory's Farmington, Connecticut headquarters. The Forum will focus on emerging science and technology that will change the future of healthcare, and innovations in healthcare.

The BIO International Convention 2019 is in Philadelphia on June 3-6, 2019. More than 16,000 biotechnology and pharma leaders will come together for intensive networking to discover new opportunities and  partnerships among a wide spectrum of life science and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.  

Cantor Colburn is pleased to be a returning sponsor of The 5th Annual JAX Healthcare Forum, which focuses on emerging science and technology that will change the future of healthcare, and innovations in healthcare. Todd E. Garabedian, Ph.D., Partner and Vice Chair of the Life Sciences Practice Group, is on the planning committee for this forum and will attend the event.

Quinnipiac University School of Business and People’s United Bank are re-opening the People’s United Center for Innovation & Entrepreneurship at a reception on October 24, 2018. Cantor Colburn attorneys Todd Garabedian, Ph.D. and David Bomzer are adjunct professors at Quinnipiac School of Law.

The 2018 BIO International Convention will take place on June 4-7, 2018, in Boston, Massachusetts. Cantor Colburn attorneys Todd Garabedian, Ph.D. and Anne Maxwell, Ph.D. will attend the 25th annual event. More than 16,500 life sciences professionals will flock to Boston for the convention.

Hartford Mayor Luke Bronin will speak at the MetroHartford Alliance Rising Star Breakfast on January 9 in Hartford.

Cantor Colburn is proud to sponsor The 4th Annual Forum on Healthcare Innovation presented by The Jackson Laboratory for Genomic Medicine on October 25-26. 2017, at the Jackson Laboratory's Farmington, Connecticut headquarters. The Forum will focus on emerging science and technology that will change the future of healthcare, and innovations in healthcare.

Stem Conn is Connecticut’s largest scientific conference, with 500 participants from academia, industry, and government. The 2017 event took place on April 27 at the Omni in New Haven.

With the first four U.S. biosimilars approved and many more in the FDA pipeline, it is critical that pharmaceutical companies develop strategies at a business operations level to comply with evolving regulations, mitigate risk and execute long-term decisions to prepare for success. At the 12th Biosimilars Summit, industry experts spoke about the tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry.

The 2016 Forum on Healthcare Innovation was presented by The Jackson Laboratory in collaboration with the Connecticut Health Council. The Forum focused on two specific topics: coverage decisions for biomedical innovation  and emerging science and technology that will change the future of healthcare.

CURE presents a deeply experienced panel of bioscience investors as they explain the venture capital trends of 2016 as well as discuss a look into the future as to where the capital will be flowing in 2017.  

Todd Garabedian, Ph.D. will present a seminar entitled, "Patent Law as a Career Path" at the Okinawa Institute of Science and Technology in Okinawa, Japan on July 6, 2016. Todd will discuss his career in patent law, as well as recent changes in patent law, including the importance of legal protection for novel intellectual assets that could have commercial implications.

Anne Maxwell, Ph.D. and Todd Garabedian, Ph.D. are attending the BIO International Convention (BIO) in San Francisco, June 6-9, 2016.

Cantor Colburn is proud to be a returning sponsor of the UConn Health White Coat Gala, which honors the “white coats” worn by the men and women breaking new ground in the lab and providing exceptional, personalized patient care.

Cantor Colburn is proud to be a returning sponsor of the UConn Health White Coat Gala.

Cantor Colburn partner Todd Garabedian, Ph.D. will speak at the University of New Haven as part of their Alvine Engineering Professional Effectiveness and Enrichment Program, Spring 2015, Speaker Series.  

Cantor Colburn partner Todd Garabedian, Ph.D., will speak on patent law and intellectual property to engineering students at the University of New Haven's the Alvine Engineering Professional Effectiveness and Enrichment Program Speaker Series.

Cantor Colburn partner Anne Maxwell, Ph.D., joins a panel discussion of the Association for Molecular Pathology v. Myriad Genetics decision and its impact on entrepreneurship In diagnostics and customized medicines at the Yale School of Medicine in New Haven on Tuesday, March 25, from 4-6 PM. This BioHaven seminar has convened a panel of experts from various sectors of the biotech and pharmaceutical industry to discuss the business implications of cases such as Myriad.